Tale of Two Cities: The Adalimumab Biosimilars Experience for Uveitis and Ocular Inflammatory Diseases at Two Texas Academic Centers.

PURPOSE: To assess appeal outcomes and factors influencing those outcomes in insurance-mandated non-medical switching (NMS) from adalimumab (Humira®) to biosimilars in patients with uveitis and ocular inflammatory diseases. METHODS: This retrospectiv…

Preview only. Read the full abstract at the source